Virtual Journal Club: Best Practices in Payer Coverage and Utilization Management of Anti-VEGF Therapies for AMD and DR/DME

Learn About:

1. Payer/provider initiatives to improve treatment
2. Benefit design strategies that facilitate appropriate evidence-based treatment for DR/DME
3. Pharmacologic treatment options for DR/DME

Expert Faculty Presenters:

Molly Beinfeld, MPH Project Director SPEC Database Click here for biography James D. Chambers, PhD, MPharm Director, SPEC Database Professor, Tufts University School of Medicine Click here for biography Jeffrey D. Dunn, PharmD, MBA President and CEO Cooperative Benefits Group (CBG) Click here for biography Jordan M. Graff, MD, FACS Surgeon & Partner, BDP Eye Center at American Vision Partners (AVP) Chair, Division of Ophthalmology, Creighton University Clinical Assistant Professor, University of Arizona, Phoenix Click here for biography

Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.

Statement of Need/Program Overview
Managed care professionals are tasked with staying up-to-date on multiple disease states to improve care management for a large and diverse patient populations. Therefore, managed care professionals can benefit from timely educational opportunities that focus on the latest clinical publications with payer implications through peer-to-peer discussion to stay informed. Commercial health plans have variable coverage criteria and step therapy protocols for anti-VEGF therapies in the management of AMD and DR/DME that are more restrictive than the FDA-labeled indications. These management strategies can increase administrative burden and delay treatment initiation, which may have adverse consequences for preserving patients’ vision. Better alignment of payer coverage policies with published evidence for anti-VEGF agents may support more timely access to care in retinal diseases.

Educational Objectives
After completing this activity, the participant should be better able to:

• Characterize pharmacologic treatment options for AMD and DR/DME in terms of efficacy, safety, and dosing intervals
• Evaluate medical and pharmacy benefit design strategies that facilitate appropriate evidence-based treatment for AMD and DR/DME
• Outline collaborative payer/provider initiatives to improve the treatment of AMD and DR/DME

Accreditation Information

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Impact Education, LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Medical Education Resources designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Medical Education Resources designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: JA0003680-9999-25-098-L01-P
This activity is certified as Knowledge-based CPE.

Please note: Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Continuing Nursing Education
Medical Education Resources designates this live activity for a maximum of 1.0 ANCC nursing contact hour. Nurses will be awarded contact hours upon successful completion of the activity.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.0 contact hour.

Disclosure of Relevant Financial Relationships
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies all relevant financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company.

The authors reported the following financial relationships with ineligible companies whose products or services may be mentioned in this activity:

The content managers reported the following financial relationships with ineligible companies whose products or services may be mentioned in this activity:

DISCLAIMER
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Impact Education, LLC, and/or Regeneron Pharmaceuticals, Inc. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

FEE INFORMATION
There is no fee for this educational activity.